This book includes a plain text version that is designed for high accessibility. To use this version please follow this link.
● Thought Leaders: Clinical Documentation

E-prescribing controlled substances moves

closer to reality But the Drug Enforcement Administration has established certain criteria that must be met.

By John Clark I

n an eff ort to fi ght the prescription drug-abuse epidemic, lawmakers in New York State recently passed legislation, known as I-STOP (Internet System for Tracking Over- Prescribing), designed to more eff ectively track patterns

of potential prescription misuse. Among its mandates, the law requires that by March 2015, all prescriptions issued in the state of New York must be done so electronically (with limited exceptions), including prescriptions for controlled substances. Electronic prescribing of controlled substances (EPCS) is a critical step in the transformation of the healthcare industry from manual to automated processes. It also improves patient safety and the accuracy of prescriptions. A recent study from the Journal of General Internal Medicine concluded that the percentage of prescription errors drops from 37 percent to 7 percent when prescribers use electronic prescribing versus paper prescriptions. In addition, EPCS streamlines workfl ows for prescribers and pharmacies, and it has the potential to reduce healthcare costs over the next decade through improvements in productivity and cost effi ciency based on the volume of prescriptions being managed. When the Drug Enforcement Administration (DEA) fi nal-

ized its rule allowing controlled substances to be prescribed electronically in 2010, it established certain criteria that must be met before a prescriber can implement EPCS. As a result, despite the potentially signifi cant advantages, EPCS has not yet been widely adopted by prescribers. Today, however, the technology and regulatory barriers to enabling EPCS have been addressed. For instance, since the DEA fi nal rule was adopted, the boards of pharmacy in 44 states have since passed regulations allowing EPCS. T e DEA also requires that both the electronic medical

records (EMR) system and the pharmacy be certifi ed for EPCS. Today, Epic, Cerner and several other EMR vendors are certi- fi ed, and there are more than 12,000 pharmacies across the U.S. certifi ed to accept prescriptions for controlled substances that were ordered electronically.

24 November 2013

T e fi nal piece to satisfying the DEA requirements and enabling EPCS is the need for two-factor authentication technology. T e DEA’s rule stipulates that any EPCS workfl ow requires two-factor authentication at the time an order for a controlled substance is placed. T is can include a combination of something only the clinician knows (such as a password), a security scan (such as the clinician’s fi ngerprint or biometric data) and/or something the clinician has (such as a token). While this is an important requirement to ensure patient safety and the accuracy of the prescription, this added layer of security has the potential to introduce complexity and decrease the effi ciency of clinical workfl ows. Healthcare CIOs and CMIOs are tasked with complying with HIPAA regulations and keeping information safe, while at the same time giving physicians the fast access they need to deliver high-quality patient care. Striking this balance when implementing EPCS can be a challenge, but there are readily available multi-factor authen- tication solutions available today that integrate with certifi ed EMR systems without disrupting workfl ow. T e most robust of these technologies support all of the authentication modalities allowed by the DEA for EPCS, which gives IT administrators more fl exibility to implement a solution that best fi ts their clinical workfl ow requirements. Given its state law mandating that all prescriptions for

controlled substances be submitted electronically by the end of 2014, New York will serve as a bellwether that will indicate the long-term patient safety and clinical workfl ow benefi ts of EPCS. However, now that the technology and regulatory barriers to adoption have been addressed, healthcare organiza- tions across the U.S. have the ability to satisfy demand from providers to enable EPCS. In the long run, this will help to better control prescription fraud and streamline the workfl ow of prescription management and administration for care pro- viders, which allows clinicians more time to focus on what matters most – patient care.


John Clark, Senior Product Manager, Imprivata.

For more on Imprivata: www.rsleads. com/311ht-201


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28